Showing 1 - 6 results of 6 for search 'Jennifer L. Leiting', query time: 0.03s Refine Results
  1. 1
    Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment

    Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment by Matthew C. Hernandez, Lin Yang, Jennifer L. Leiting, Takaaki Sugihara, John R. Bergquist, Tommy Ivanics, Rondell Graham, Mark J. Truty

    Published 2019-01-01
    Get full text
    Article
  2. 2
    In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts

    In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts by Jaena Park, Janet E. Sorrells, Eric J. Chaney, Amro M. Abdelrahman, Jennifer A. Yonkus, Jennifer L. Leiting, Heidi Nelson, Jonathan J. Harrington, Edita Aksamitiene, Marina Marjanovic, Peter D. Groves, Colleen Bushell, Mark J. Truty, Stephen A. Boppart

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States

    Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States by Amro M. Abdelrahman, Jun Yin, Roberto Alva-Ruiz, Jennifer A. Yonkus, Jennifer L. Leiting, Isaac T. Lynch, Alessandro Fogliati, Nellie A. Campbell, Danielle M. Carlson, Lewis R. Roberts, Gregory J. Gores, Rory L. Smoot, Rondell P. Graham, Thorvardur R. Halfdanarson, Mark J. Truty

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine

    Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine by Jennifer L. Leiting, Stephen J. Murphy, John R. Bergquist, Matthew C. Hernandez, Tommy Ivanics, Amro M. Abdelrahman, Lin Yang, Isaac Lynch, James B. Smadbeck, Sean P. Cleary, David M. Nagorney, Michael S. Torbenson, Rondell P. Graham, Lewis R. Roberts, Gregory J. Gores, Rory L. Smoot, Mark J. Truty

    Published 2020-04-01
    Get full text
    Article
  5. 5
    Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts

    Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts by Faizal Z. Asumda, Nellie A. Campbell, Mohamed A. Hassan, Reza Fathi, Daniella F. Vasquez Rico, Melanie Kiem, Ethan V. Vang, Yo Han Kim, Xin Luo, Daniel R. O’Brien, Sarah A. Buhrow, Joel M. Reid, Michael J. Moore, Vered Katz Ben-Yair, Mark L. Levitt, Jennifer L. Leiting, Amro M. Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J. Truty, Lewis R. Roberts

    Published 2024-03-01
    Get full text
    Article
  6. 6
    The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative

    The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative by Jennifer L. Leiting, Courtney N. Day, William S. Harmsen, Jordan M. Cloyd, Sherif Abdel-Misih, Keith Fournier, Andrew J. Lee, Sean Dineen, Sophie Dessureault, Jula Veerapongh, Joel M. Baumgartner, Callisia Clarke, Harveshp Mogal, Maria C. Russell, Mohammad Y. Zaidi, Sameer H. Patel, Mackenzie C. Morris, Ryan J. Hendrix, Laura A. Lambert, Daniel E. Abbott, Courtney Pokrzywa, Mustafa Raoof, Oliver Eng, Fabian M. Johnston, Jonathan Greer, Travis E. Grotz

    Published 2020-01-01
    Get full text
    Article

Search Tools: